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Abstract
Human cytomegalovirus (HCMV) is familiar to pediatric rheumatologists mainly as a cause of opportunistic disease in 
pharmacologically immune suppressed patients. However, HCMV also has a variety of immuno-modulatory effects, 
through which it may influence the course of rheumatic conditions. In this article we discuss the interplay between 
HCMV and the immune system, and review the clinical manifestations, diagnosis, and treatment of HCMV infection in 
children with rheumatic disease.
Introduction
Human cytomegalovirus (HCMV) is a ubiquitous beta-
herpesvirus that causes symptoms primarily in immune-
compromised individuals. Fully assembled virus is com-
prised of a DNA-containing capsid surrounded by a tegu-
ment layer and lipid envelope. The viral genome contains
over 200 open reading frames [1].
HCMV is well-known to pediatric rheumatologists as
an opportunistic pathogen. However, this virus also pos-
sesses immuno-modulatory properties, and may be a co-
factor in the pathogenesis of certain forms of rheumatic
disease. In this review, we discuss clinical and immuno-
logic aspects of HCMV infection relevant to the practice
of pediatric rheumatology.
Epidemiology of HCMV infection
Sero-epidemiologic data indicate that between 30-70% of
children in the United States have been infected with
HCMV by school age [2]. The prevalence of anti-HCMV
IgG antibodies is higher in minority children and those in
developing countries, and continues to increase through-
out life [3]. Humans are the only known host for HCMV,
and infection requires contact with infected secretions.
Common routes of infection include horizontal passage
among family members, sexual transmission, vertical
intra-uterine transmission, and breastfeeding. Children
may continue to secrete virus for months or even years
following primary infection, making them an important
reservoir of infectious virus. Infection may be acquired
though sexual contact in adolescents and adults [4]. Ver-
tical transmission from mother to fetus can occur
throughout pregnancy. Primary infection during the first
trimester confers the greatest risk for severe congenital
disease [5]. Transfusion of infected blood products and
transplantation of infected organs are important sources
of HCMV infection in the nosocomial setting.
HCMV latency and re-activation
H C M V  e x i s t s  i n  t w o  f o r m s :  a s  a n  a c t i v e l y  r e p l i c a t i n g
virus, and in a latent form. Latency is defined as persis-
tence of non-replicating viral DNA in cells, that has the
potential to re-activate and form infectious virus under
propitious conditions [6]. While replicating in vivo,
HCMV is capable of producing lytic infection in numer-
ous cell types, including epithelial and endothelial cells,
fibroblasts, and dendritic cells. In contrast, latent HCMV
a p p e a r s  t o  b e  r e s t r i c t e d  m a i n l y  t o  m y e l o i d - d e r i v e d
monocyte and dendritic cell precursors [7], including
CD34+ pluripotent cells [8], although it is possible that
latent virus is also present in other tissues. The tissue-
specificity of latent HCMV is clinically significant, in that
filtration of blood products to remove nucleated cells
reduces the likelihood of HCMV transmission to transfu-
sion recipients. Viral re-activation requires cellular differ-
entiation, which in turn is influenced by various
cytokines [9]. The principal molecular determinant of
viral activation from the latent state is expression of the
immediate early (IE) gene, which is under the control of
the major IE promoter/enhancer (MIEP). MIEP activity is
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regulated by several activating and inhibiting transcrip-
tion factors that are expressed in myeloid cells [10].
The pro-inflammatory cytokine tumor necrosis factor-
α (TNFα) enhances replication of HCMV in monocytes,
and this effect is potentiated by interferon-γ [11]. More-
over, high serum concentrations of TNFα are associated
with increased viral load in recipients of solid organ [12]
or bone marrow transplants [13]. Thus, in general, a pro-
inflammatory cytokine milieu appears to favor HCMV
re-activation. Pediatric rheumatic diseases with a sys-
temic component are also characterized by increased
concentrations of pro-inflammatory cytokines in the
peripheral blood, [14-16], suggesting that the likelihood
of clinically significant HCMV infection may be
increased in the setting of uncontrolled rheumatic dis-
ease.
HCMV-Immune Interactions
Both innate and adaptive immune mechanisms are essen-
tial for control of HCMV. The importance of cellular
immunity is apparent from the frequency and severity of
i n f e c t i o n s  o b s e r v e d  i n  p a t i e n t s  w i t h  c o n g e n i t a l  o r
acquired cellular immune defects. Indeed, the extent of
HCMV replication can be used as a barometer to gauge
the degree of cellular immune suppression [17]. Both
CD4+ and CD8+ T lymphocytes are required for full
anti-HCMV immunity [18]. However, as would be
expected for an intra-cellular pathogen, CD8+ T cell
mediated immunity against antigen presented by Class I
MHC molecules appears to be critical for control of viral
replication. During viral latency, up to 10% of all CD8+ T
cells in the peripheral blood may recognize HCMV
epitopes [19]. These cells are comprised of relatively few
clones that have expanded greatly [20]. The pp65 tegu-
ment protein is the most promiscuous target of the anti-
HCMV T cell response [21], while appearance of anti-IE-
specific CD8 T cell clones has also been correlated with
protection against HCMV infection in solid organ trans-
plant recipients [22].
The importance of natural killer (NK) cells in anti-
CMV immunity is inferred from experiments in mice
infected by murine cytomegalovirus (MCMV). In these
studies, animals deficient in NK cell function are suscep-
tible to severe MCMV disease. Anti-MCMV activity
appears to be confined to a specific NK cell subset [23].
Cases of severe HCMV disease in humans with impaired
NK cell function have been reported [24,25]. Anti-
HCMV hyper-immune globulin appears to have some
efficacy for prevention of primary HCMV infection in
solid organ transplant recipients, and there is evidence
that intravenous hyperimmune anti-HCMV globulin may
prevent vertical transmission of HCMV during preg-
nancy [26]. These findings point to a role for humoral
immunity in control of HCMV.
HCMV possesses a variety of mechanisms which
enable it to evade the immune response during active
replication and possibly during latency. The best charac-
terized of these mechanisms is the capacity to down-reg-
ulate MHC Class I molecule expression [27].
I n t e r e s t i n g l y ,  M H C - I  d o w n  r e g u l a t i o n  p e r  s e  d o e s  n o t
prevent emergence of a robust anti-HCMV CD8+ T cell
response [28]. Numerous other mechanisms for evasion
of cell-mediated immunity have been described, includ-
ing inhibition of MHC-II expression [29] and expression
of a viral homologue of the naturally occurring human
immunosuppressive cytokine interleukin-10 [30].
HCMV is capable of inhibiting NK cell activation by
several mechanisms [31]. Some of the more interesting of
these include a specific inhibitory interaction between
the HCMV pp65 tegument protein and an NK cell acti-
vating receptor, NKp30 [32], and a recently described
form of NK cell inhibition via viral micro-RNA [33].
Clinical HCMV disease in children
Primary HCMV infection in immune-competent chil-
dren may sometimes result in an acute, self-limited
mononucleosis-like illness, but more commonly is
asymptomatic and goes unrecognized [1]. Re-infection by
an antigenically un-related strain may also occur, with the
same clinical consequences [34].
HCMV infection in immune-suppressed patients [35],
including those with severe combined immune defi-
ciency, acquired immune deficiency syndrome [36], or
recipients of bone marrow [37] or solid organ transplants
[38] is usually caused by re-activation of latent virus, and
may cause severe, life threatening disease. As noted
above, during active replication, HCMV is capable of
infecting numerous types of cells, resulting in involve-
ment of multiple organ systems including the lung, eye,
intestine, and central nervous system. However, signs and
symptoms of HCMV infection may also be subtle or non-
specific, and a high index of suspicion may be required
for prompt diagnosis.
CMV infection in patients with rheumatic disease
HCMV re-activation is well-recognized in both adult and
pediatric patients with rheumatic disease. In systemic
lupus erythematosis (SLE), HCMV disease occurs mainly
in individuals receiving potent immune suppressive regi-
mens [39]. However, infection has also been described in
patients receiving little or no medication to control their
disease [40], suggesting that underlying immune dysregu-
lation may predispose lupus patients to HCMV re-activa-
tion. Protean clinical sequelae, including retinitis [41],
pneumonitis [42], hepatitis [43], esophagitis [40], enteri-
tis [44], pancreatitis [45], and hematologic abnormalities
[46] have been described, making it sometimes difficult
to distinguish infection from a lupus flare on clinicalEisenstein and Wolf Pediatric Rheumatology 2010, 8:17
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grounds. Moreover, HCMV infection may trigger a lupus
exacerbation [47,48], emphasizing the possibility that
more than one disease process may be present in a given
patient. HCMV infection in lupus is a potential trigger for
macrophage activation syndrome (MAS, discussed fur-
ther below) and may be associated with high rate of mor-
tality [49], underscoring the need to consider HCMV
along with other viral infections as a potential cause of
unexplained clinical deterioration of a lupus patient.
Opportunistic HCMV disease has also been described
in other rheumatic diseases that include a significant
component of systemic illness. In recent multi-center
survey which included adult and pediatric patients hospi-
talized for rheumatic diseases in Japan [50], HCMV infec-
tion was identified on the basis of a positive pp65
antigenemia test or histopathology in 151/7377 patients.
Among those who tested positive for HCMV antigene-
mia, 117 were symptomatic. The most common rheu-
matic diagnoses were SLE, dermatomyositis, mixed
connective tissue disease, rheumatoid arthritis, and vari-
ous forms of systemic vasculitis. Many were receiving
combination immunosuppressive treatment, including
glucocorticoids and cytotoxic drugs. Significantly, how-
ever, 27 patients developed HCMV infection while
receiving oral prednisone without other immunosuppres-
sive drugs. High-dose pulse methylprednisolone treat-
m e n t  w a s  a s s o c i a t e d  w i t h  p a r t i c u l a r l y  h i g h  r i s k  f o r
HCMV infection.
Few data concerning the risk for HCMV infection con-
ferred by individual immunosuppressive drugs other than
glucocorticoids are available. However, re-activation of
another herpes virus, varicella-zoster virus, during treat-
ment for rheumatic diseases has been examined. In one
study, the hazard ratio for zoster in adult patients receiv-
ing cyclophosphamide was 4.2, azathioprine 2.0, predni-
sone 1.5, leflunamide 1.4, and methotrexate 1.0 [51]. Fatal
HCMV infection has been reported in a patient with
juvenile idiopathic arthritis treated with azathioprine
[52]; it is unknown whether this child was deficient of an
enzyme critical for azathioprine metabolism, thiopurine
methyltransferase. Leflunamide has anti-HCMV activity
in vitro [53], but it is unclear whether this property out-
weighs its immune suppressive effects. Reports concern-
ing whether infliximab treatment confers increased
susceptibility to HCMV infection have yielded conflicting
findings [54,55], but it appears that patients receiving
TNFα antagonists may be at mildly increased risk for
HCMV re-activation [56]. Information concerning the
risk for HCMV disease posed by other biologic agents is
limited. No cases of HCMV disease in patients receiving
rituximab for rheumatic disease have been reported to
date. However, rituximab has been associated with severe
or fatal HCMV infections in lymphoma patients, and it
has been suggested that oncologic patients should be
monitored for HCMV during rituximab therapy [57,58].
HCMV as a possible cause of arthritis
At present, there is little evidence to support a role for
HCMV in the pathogenesis of arthritis. Low amounts of
HCMV DNA have been detected in the peripheral blood
[59] and joints [60] of adults with rheumatoid arthritis.
The etiologic significance of these findings is unclear. The
literature describing HCMV infection in pediatric rheu-
matic diseases is even more limited than in adult patients.
In one study using non-quantitative PCR techniques, the
prevalence of HCMV DNA in leukocytes obtained from
children with SLE and JIA was found to be similar to con-
trols [61].
Possible role of HCMV in SLE and other autoimmune 
diseases
A number of studies have examined the possibility that
HCMV infection may be a co-factor in the pathogenesis
of SLE. In most, serologic methods were used to detect
anti-CMV IgM and IgG antibodies. As discussed below,
these tests may be unreliable in patients receiving immu-
nosuppressive drugs. Furthermore, it is difficult to know
whether detection of antibodies reactive with viral
epitopes in individuals with an autoimmune disease is a
cause or result of immune dysregulation.
With these caveats in mind, at least five reports in have
examined anti-CMV antibodies in the sera of adult SLE
patients [62-66]. With one exception [62], these studies
have found that the prevalence of anti-CMV IgG antibod-
ies is similar in lupus patients to that in the control popu-
lation. In contrast, in four reports, the prevalence of anti-
CMV IgM antibodies was increased in lupus patients as
compared to controls, and in three [64-66] the increase
was statistically significant. Several possible mechanisms
for these findings have been proposed, including anti-
genic mimicry, epitope spreading, immune activation by
a putative viral superantigen, polyclonal B cell activation,
and viral re-activation in the context of immune suppres-
sion [67]. Only one small study examining HCMV viral
l o a d  i n  S L E  p a t i e n t s  h a s  b e e n  r e p o r t e d .  I n  t h i s  s t u d y ,
HCMV copy number was not increased in the peripheral
b l o o d  o f  S L E  p a t i e n t s  a s  c o m p a r e d  t o  h e a l t h y  c o n t r o l
donors [68].
Other investigators have examined the possibility that
specific HCMV epitopes may induce auto-antibodies
with a potential role in the pathogenesis of SLE or mixed
connective tissue disease. These studies were prompted
in part by pre-clinical vaccine studies which showed that
immunization of mice with a candidate HCMV vaccine
expressing the HCMV UL-55 (glycoprotein B) antigen
elicited production of anti-U1 70kd protein antibodies
[69]. These auto-antibodies were not detected in humanEisenstein and Wolf Pediatric Rheumatology 2010, 8:17
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subjects following immunization with either of two can-
didate vaccines expressing CMV glycoprotein B antigen
[70]. Reports examining the prevalence of anti-U1 70kd
antibodies in anti-CMV adult sero-positive SLE patients
have yielded conflicting results [71,72]. One recent study
found that among SLE patients who are sero-positive for
anti-CMV antibodies, antibodies against certain auto-
antigens including U1 70kd protein are particularly fre-
quent in patients who were anti-CMV IgG positive but
anti-CMV IgM negative [73]. The significance of this
finding is uncertain. In summary, while there appears to
be an association between certain anti-CMV antibodies
and SLE, further study will be required to elucidate
whether they have any patho-physiologic significance.
MCMV has been shown to induce sialadenitis reminis-
cent of Sjögren's syndrome in C57Bl/6-lpr/lpr mice [74].
The relevance of this model to human disease is uncer-
tain. Two cases of anti-phospholipid syndrome with deep
venous thrombosis associated with anti-CMV IgM and
IgG antibodies have been reported [75,76].
CMV as a possible trigger of macrophage activation 
syndrome
Macrophage activation syndrome (MAS) is a potentially
fatal condition characterized clinically by fever, lymph-
adenopathy, central nervous system involvement, hepati-
tis that may progress to fulminant hepatic failure,
coagulopathy, and hemophagocytosis in the bone mar-
row. Evidence of occult MAS may be detected in as many
as half of patients with systemic onset juvenile idiopathic
arthritis (SJIA). MAS has also been described in SLE and
other pediatric rheumatic diseases [77,49].
MAS closely resembles another syndrome of immune
dys-regulation and inflammation, termed hemophago-
cytic lymphohistiocytosis (HLH) that occurs in both
familial and sporadic forms. Familial HLH occurs as a
result of genetic defects in molecules essential for normal
NK cell function [78]. For this reason, NK cell function
has also been studied in MAS. These studies revealed
that as in HLH, NK cell function is impaired in approxi-
mately 50% of children with MAS [79], and more recent
gene expression data have shown that NK-cell related
genes are down-regulated in children with SJIA compli-
cated by MAS [80]. Taken together, these findings suggest
that NK cell defects may have an important role in the
pathogenesis of MAS.
Rarely, polymorphisms in genes essential to normal NK
cell function can be demonstrated in children with MAS
[81]. However, in the majority of cases of SJIA- associated
MAS there is no known genetic explanation for NK cell
dysfunction. However, one possible hypothesis that might
explain these NK cell abnormalities is immunomodula-
tory effects of herpes viruses. In this regard, using molec-
ular techniques, HCMV or Epstein-Barr virus DNA can
be demonstrated in the peripheral blood of about half of
these patients [82]. As noted above, herpes viruses are
capable of attenuating NK cell function through a variety
of specific molecular interactions. Moreover, herpesvi-
ruses, including HCMV, Epstein-Barr virus, and human
herpesvirus-6 are well recognized triggers for HLH [83].
Taken together, these observations suggest that herpesvi-
ruses including HCMV may be a trigger for MAS, and
they should be sought in children with rheumatic disease
who present with this complication.
Laboratory diagnosis of HCMV infection
Serologic tests for anti-HCMV specific antibodies are
used to diagnose primary infection in immune-compe-
tent persons. While the presence of anti-HCMV IgM
antibody may indicate primary or recurrent infection, the
value of this test is limited by sub-optimal sensitivity, dis-
cordance of results between different commercial kits,
and variable persistence of antibody following primary
infection. Furthermore, results may be influenced by the
presence of rheumatoid factor or heterophile antibodies
caused by infection by Epstein Barr virus [84]. Finally, as
indicated above, the presence of anti-HCMV IgG anti-
bodies does not imply full protective immunity against
HCMV infection, since both viral re-activation and re-
infection may occur. Serologic testing is not considered
reliable for diagnosis of infection in the setting of com-
promised immunity [85].
The advent of direct antigenic and molecular testing
has revolutionized the diagnosis of HCMV infection in
the setting of immune suppression. HCMV pp65 antigen-
emia or quantitative polymerase chain reaction (PCR)
based tests can be used for direct detection of virus in
peripheral blood lymphocytes with semi-quantitative or
quantitative measurement of viremia, respectively. Viral
load has proven useful for diagnosis of infection, predic-
tion of disease, and monitoring response to therapy
[86,87]. One should keep in mind that detection of small
amounts of viral DNA in peripheral blood by PCR is not
necessarily indicative of clinically significant HCMV
infection, and correct interpretation of test results may
require consultation with the virology laboratory or an
infectious diseases specialist. Further confirmatory diag-
nosis of organ specific involvement can be made by histo-
logic detection of characteristic inclusion bodies
contained in cells from bronchoalveolar lavage fluid, or
tissue biopsy specimens. Other techniques for identifying
HCMV in tissue include immunohistochemistry, in situ
hybridization, and electron microscopy [88]. Confirma-
tion of tissue infection by viral culture may be of interest
in retrospect, but culture is usually too slow to be useful
for patient management.Eisenstein and Wolf Pediatric Rheumatology 2010, 8:17
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Treatment of clinically significant HCMV infection in a
child with systemic rheumatic disease consists of reduc-
ing the level of immune suppression to the minimum
necessary to avoid acute immune-mediated complica-
tions of disease, and specific anti-viral therapy. Three
drugs are currently approved for treatment of severe
HCMV disease: ganciclovir, foscarnet, and cidofivir. Each
target the same molecule, the viral DNA polymerase. In
general, the use of anti-HCMV drugs in clinical practice
is currently limited by dose-dependent toxicity. Intrave-
nous gancyclovir in considered the first drug of choice for
severe disease. Emergence of resistant strains has been an
increasing concern in the transplant setting. Most ganci-
clovir resistance is due to mutations in the HCMV UL97
or DNA polymerase genes [89]. Testing for these muta-
tions is available in reference laboratories in situations
when treatment fails to reduce viral load. Other anti-viral
drugs can be used for treatment of resistant strains,
although cross-resistance may develop. Recently, oral val-
ganciclovir has been increasingly used as an alternative to
intravenous ganciclovir for prophylaxis and treatment of
HCMV disease in specific settings [90]. The role of this
drug in the management of HCMV infection in patients
with rheumatic disease remains to be defined.
Summary
HCMV disease may occur as a consequence of re-activa-
tion of latent virus in children receiving immunosuppres-
sive drugs for systemic rheumatic disease. Patients with
uncontrolled inflammation who are receiving immuno-
suppressive medications appear to be at particularly high
risk. Since the clinical manifestations of HCMV disease
are protean, antigenic or PCR-based tests should be used
to detect this virus in a child with systemic rheumatic dis-
ease who fails to respond as expected to immunosuppres-
sive treatment. In addition, infection by HCMV and other
human herpesviruses should be sought in children with
macrophage activation syndrome, as these viruses are
both common and potential triggers for this complica-
tion.
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